A Reversible Gastric Uptake of Bone Scintigraphy in a Patient with Hypercalcemia

Intern Med. 2019 Jun 1;58(11):1583-1586. doi: 10.2169/internalmedicine.2115-18. Epub 2019 Feb 1.

Abstract

Hypercalcemia is a severe complication in cases of vitamin D intoxication that can result in metastatic calcification. We herein report a female case with hypercalcemia due to eldecalcitol administration associated with the increased uptake of technetium-99m hydroxymethylene diphosphonate (99mTc-HMDP) as the bone-scanning agent in the stomach. A histologic assessment using biopsy specimens identified metastatic calcification of the stomach. After the normalization of serum calcium levels, the gastric uptake of 99mTc-HMDP disappeared. This case indicates the usefulness of bone scintigraphy with 99mTc-HMDP to detect visceral metastatic calcification and to monitor its therapeutic effects in patients with hypercalcemia.

Keywords: bone scintigraphy; hypercalcemia; kidney disease; metastatic calcification; vitamin D.

Publication types

  • Case Reports

MeSH terms

  • Bone Density Conservation Agents / adverse effects
  • Calcinosis / diagnostic imaging*
  • Calcinosis / etiology
  • Female
  • Humans
  • Hypercalcemia / complications*
  • Middle Aged
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Stomach Diseases / diagnostic imaging*
  • Stomach Diseases / etiology
  • Technetium Tc 99m Medronate / analogs & derivatives
  • Tomography, X-Ray Computed
  • Vitamin D / adverse effects
  • Vitamin D / analogs & derivatives

Substances

  • Bone Density Conservation Agents
  • Radiopharmaceuticals
  • Vitamin D
  • technetium Tc 99m hydroxymethylene diphosphonate
  • eldecalcitol
  • Technetium Tc 99m Medronate